関連する実験動画
Updated: Jan 6, 2026
01:19
Mitral Valve Prolapse III: Nursing Management
Published on: June 19, 2025
252
血管内磁気共鳴画像による人間の動脈硬化プラークの特徴化
Eric Larose1, Yerem Yeghiazarians, Peter Libby
1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Circulation
|October 6, 2005
まとめ
静脈内MRI (静脈内MRI) は,深層動脈における動脈硬化性プラークの構成と大きさを正確に特定することができます. このイメージング技術は,ヒト動脈硬化症の改善された理解と潜在的な改変戦略を提供します.
科学分野:
- 心血管画像検査 (CVDI) について
- バイオメディカルエンジニアリング
- 放射線学 放射線学
背景:
- 動脈硬化性プラークの組成を評価することは,動脈瘤の進化と治療戦略を理解するために重要です.
- 表面MRIは表面動脈に限られており,より深い血管には高度な技術が必要です.
- 血管内MRI (Intravascular MRI,IVMRI) は,人間の動脈内のプラークを特徴づける可能性のために調査されました.
研究 の 目的:
- 血管内MRI (IVMRI) の有効性を評価するために,ヒトの動脈の組成を in vivo で識別する.
- IVMRIの性能を血管内超音波 (IVUS) と比較して,プラークの特徴を決定する.
主な方法:
- IVMRI検証は,ヒト動脈硬化動脈のex vivo組織病理学に対して行われました.
- 0.030インチのIVMRIコイルを1.5Tスキャナーと共に使用し,T1,T2,および陽子密度加重画像を取得した.
- このテクニックは25人のヒト被験者にインビヴォで適用され,IVUSと比較した結果が得られました.
主要な成果:
- IVMRIは,高感度および特異性を持つ脂質,繊維,およびカルシ化されたプラーク成分を成功裏に微分化しました.
- IVMRIは,IVUSが失敗した加熱動脈でも,プラークの大きさを正確に定量化し,境界線を視覚化しました.
- IVMRIは,プラーク組成の解釈において,IVUS.より優れている高いインターおよびイントラオブザーバー合意を示しました.
結論:
- 静脈内MRI (静脈内MRI) は,深い動脈のプラークの構成と大きさを特定するための信頼できるツールです.
- IVMRIのプラークをインビヴォで特徴づける能力は,動脈硬化症の研究と治療の進歩に大きな意味を持っています.
関連する概念動画
Mitral Valve Prolapse III: Nursing Management
252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines
917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence
759
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations
51.1K
Overview
51.1K
Healthcare Associated Infections II: Preventive Measures
3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K